secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134733
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports durable FVIII activity >16 mo in NHP hemophilia A study; MGX-001 IND on track for 2026
--------------------------------------------------------------------------------

- FVIII activity sustained across 13-16.5 months in NHPs: 72%, 9%, 30% at 16.5 mo; integration freq 0.7-3.1%.
- MGX-001 bioengineered FVIII showed higher activity vs wild-type at similar integration rates in separate NHP study.
- No off-target editing identified to date in orthogonal assays; program targeting IND filing in 2026.
- Transient liver transaminase elevation at AAV/LNP dosing; no safety findings on albumin or bilirubin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/0000950170-24-134733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024134733/mgx-20241209.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer